Connect with us

Top Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021

Biotech penny stocks continue to see momentum; should you add these 4 to your watchlist?
The post Top Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

3 years ago

on

Will These Biotech Penny Stocks Pop Next Month?

Biotech penny stocks have become some of the most popular stocks to watch throughout the Covid pandemic. And while the obvious explanation for this is the relationship between biotech and Covid, there are some less obvious factors to consider. 

For one, the pandemic has helped to emphasize a large range of biotech companies that are not working on a Covid treatment. This is because investors have continued to focus on companies that have a large pipeline of promising assets rather than ones only working on a vaccine or treatment. 

The next thing to consider is that there are a lot of biotech penny stocks working on either treatments or vaccines for Covid-19. These companies can be more volatile than others, but the potential can also be quite high. 

4 Biotech Penny Stocks to Watch Right Now

Now, when looking for a biotech penny stock to buy, there are a few things to consider. First and foremost is, what does its pipeline look like? This includes knowing how many drugs it has in development, and where those drugs are in the various stages of approval. 

[Read More] 3 Penny Stocks on Robinhood for Your April Watchlist

Next, how is its financial situation? Has it engaged in any fundraising rounds or does it have a large balance of cash on hand? This information can help to identify potential long-term business opportunities and whether or not it can fund ongoing/future trials and research. 

These are all equally important aspects to consider for all prospective biotech investors. So with this in mind, are these the top penny stocks to buy for May 2021?

  1. Iterum Therapeutics Plc. (NASDAQ: ITRM) 
  2. Onconova Therapeutics Inc. (NASDAQ: ONTX) 
  3. Asensus Surgical Inc. (NYSE: ASXC)
  4. Zomedica Corp. (NYSE: ZOM)

1. Iterum Therapeutics Plc. (NASDAQ: ITRM) 

Iterum is a clinical-stage pharmaceutical company working on the production of anti-infectives. These compounds are used for a variety of drug-resistant pathogens around the world. Its flagship compound known as sulopenem is a novel anti-infective that is currently in a Phase 3 trial to see its efficacy in treating antibiotic-resistant anaerobic infections. 

Iterum states that it has received QIPD or Qualified Infectious Disease Product and Fast Track Designations for both the oral and intravenous formulations of sulopenem in seven different indications. Last month, Iterum announced its fourth quarter and full-year 2020 results. 

[Read More] Top Penny Stocks This Week? 3 To Watch During Crypto Boom

Corey Fishman, CEO of the company stated that “Iterum has made excellent progress in the last few months and we look forward to continuing that momentum throughout 2021. In the fourth quarter of 2020, we submitted a New Drug Application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with a quinolone non-susceptible organism, which is currently under review by the FDA with a July 25th, 2021 Prescription Drug User Fee Act (PDUFA) goal date.” 

Only a month before this, the company announced the increase of its share offering to 40 million shares, bringing in aggregate net proceeds of around $42.1 million. This should help to fund the rest of the sulopenem trial as well as the commercial launch of this compound. Considering its role in the biotech industry, is ITRM stock worth watching?

2. Onconova Therapeutics Inc. (NASDAQ: ONTX) 

Onconova is another pure-play biotech penny stock working on clinical-stage pharmaceuticals. Its focus is on treatments for cancer, including targeted anti-cancer therapeutics that disrupt specific cellular pathways. This includes its proprietary multi-kinase inhibitor known as ON-123300. This compound is beginning a dose-escalation and expansion Phase 1 trial in the U.S. The data from this study should be coming in the second quarter of this year. 

Additionally, a similar trial is currently ongoing in China. Another interesting part of its pipeline is the compound rigosertib. This is in preclinical trials right now for its efficacy in treating Covid-19. 

On April 22nd, the company announced that its first patient was dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma (RDEB).

Steven Fruchtman, M.D., CEO of Onconova, stated that “we are pleased with the advancement of our investigator-initiated programs with rigosertib, and to provide rigosertib in support of this important Phase 2 investigator-sponsored study…We hope rigosertib can prove beneficial to this rare patient population with a tremendous unmet medical need.” 

This comes only a few weeks after the company announced full enrollment in the second cohort of its China-based study of ON-123300 with HanX Biopharmaceuticals. In this trial, the goal is to see ON-123300’s efficacy in the treatment of metastatic breast cancer and other advanced refractory cancers. 

Considering its exciting pipeline, it looks like Onconova could be an interesting penny stock to watch. Additionally, shares of ONTX stock have jumped by around 47% YTD, including a double-digit gain on April 22nd. Whether this puts it on your watchlist is up to you. 

Penny_Stocks_to_Watch_Onconova Therapeutics Inc. (ONTX Stock Chart)

3. Asensus Surgical Inc. (NYSE: ASXC)

Asensus Surgical is penny stock that we’ve covered quite a few times in the past few months. The reason being, its solid pipeline of potentially valuable assets. The company states that it is creating “a new standard of surgery for increased control, less variability and consistently superior outcomes.” 

Its main product aims to use AI to improve the outcomes of both common and more intensive surgical procedures. The majority of its market is based on providing the tools to conduct elective surgeries more safely and effectively. 

When the pandemic first began, many individuals decided to forgo elective surgeries for the time being. However, as the months passed and cases dropped, these surgeries began to occur at almost pre-covid levels.

[Read More] 4 Trending Penny Stocks to Watch in April 2021

Because of this, some investors believe that Asensus and its flagship Performance-Guided Surgery products could see a major increase in demand in the coming months or years. This includes its Senhance Surgical System, which recently received an expanded 510(k) clearance for use in general surgery applications. 

Additionally, its Intelligent Surgical Unit, or ISU, recently was awarded a CE Mark in Europe. In the latest fourth-quarter result, the CEO of the company gave a statement regarding the company’s current and future operations.

“We are very pleased with the momentum we generated during 2020 and particularly during the fourth quarter. This momentum continued into the early part of 2021 where we have already accomplished a number of significant milestones, including the bolstering of our balance sheet, the rebranding of the organization, and the introduction of our vision for Performance-Guided Surgery.”

CEO of Asensus Surgical Inc., Anthony Fernando

With all of this exciting news in mind, is ASXC a penny stock to watch or not?

Penny_Stocks_to_Watch_Asensus Surgical Inc. (ASXC Stock Chart)

4. Zomedica Corp. (NYSE: ZOM)

Shares of Zomedica continued rebounding on April 22nd. This marked the second day in a row that the medical device stock headed back toward the $1 mark. The company’s main focus is on commercial sales of its recently launched diagnostic device, TRUFORMA.

The platform offers total control over the testing process for animals. It offers highly sensitive and specific immunoassays that allow veterinarians to make clinical decisions “faster and begin treating patients sooner.”

Last quarter was the big update that traders have waited for since 2020: the commercial launch of TRUFORMA. Now Zomedica is looking to expand its salesforce and go direct to customers.

Earlier in the month, the company announced that it expanded its sales organization. Brük Herbst, Chief Commercial Officer of Zomedica, explained that “A direct sales force will significantly improve our ability to serve our customers and to sell our products in the veterinary market in the longer term.”

If you’re unfamiliar with the backstory of Zomedica over the last few months, it has included everything from Reddit traders to Carol Baskin of the show Tiger King. Speculation on the launch of commercial sales has helped drive ZOM stock from under $0.10 to over $2.90. But since February, shares have been in a constant decline as traders await the results of advanced sales efforts.

Thanks to recent news on expansionary plans, the market has seen an uptick in momentum. Furthermore, over the last 2 sessions, ZOM stock has jumped by as much as 32% so far. Will it still be one of the penny stocks under $1 this time next week?

Penny_Stocks_to_Watch_Zomedica Corp. (ZOM Stock Chart)

The post Top Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Related Topics:
Continue Reading

Government

QE By A Different Name Is Still QE

The Fed added Quantitative Easing (QE) to its monetary policy toolbox in 2008. At the time, the financial system was imploding. Fed Chair Ben Bernanke…

Published

3 hours ago

on

March 20, 2024

By

The Fed added Quantitative Easing (QE) to its monetary policy toolbox in 2008. At the time, the financial system was imploding. Fed Chair Ben Bernanke bought $1.5 trillion U.S. Treasury and mortgage-backed securities to staunch a financial disaster. The drastic action was sold to the public as a one-time, emergency operation to stabilize the banking system and economy. Since the initial round of QE, there have been four additional rounds, culminating with the mind-boggling $5 trillion operation in 2020 and 2021.

QE is no longer a tool for handling a crisis. It has morphed into a policy to ensure the government can fund itself. However, as we are learning today, QE has its faults. For example, it’s not an appropriate policy in times of high inflation like we have.

That doesn’t mean the Fed can’t provide liquidity to help the Treasury fund the government’s deficits. They just need to be more creative. To that end, rumors are floating around that a new variation of QE will help bridge potential liquidity shortfalls.

The Sad Fiscal Situation

The Federal government now pays over $1 trillion in interest expenses annually. Before they spend a dime on the military, social welfare, or the tens of thousands of other expenditures, one-third of the government’s tax revenue pays for the interest on the $34 trillion in debt, representing deficits of years and decades past.

There are many ways to address deficits and overwhelming debt, such as spending cuts or higher taxes. While logical approaches, politicians favor more debt. Let’s face it: winning an election on the promise of spending cuts and tax increases is hard. It’s even harder to keep your seat in Congress if you try to enact such changes.   

More recently, the Federal Reserve has been forced to help fund today’s deficits and those of years past. We can debate the merits of such irresponsible behavior all day, but for investors, it’s much more critical to assess how the Fed and Treasury might keep the debt scheme going when QE is not an option.

Borrowing For Deficits

Before spreading rumors about a new variation of QE, let’s review the problem. The graph below shows the widening gap between federal spending and tax receipts. Literally, the gap between the two lines amounts to the cumulative Federal deficit. Instead of plotting deficit data, we prefer outstanding total federal debt as it better represents the cumulative onus of deficits.

treasury deficits expenditures and tax revenues debts

The graph below shows the Treasury debt has grown annually for the last 57 years by about 1.5% more than the interest expense. Such may not seem like a lot, but 57 years of compounding makes a big difference.  

Declining interest rates for the last 40+ years are to thank for the differential. The green line shows the effective interest rate has steadily dropped until recently. Even with the current instance of higher interest rates, the effective interest rate is only 3.00%.

treasury debt

Fiscal Dominance

The Fed has been increasingly pressed to help the U.S. Treasury maintain the ability to fund its debt at reasonable interest rates. In addition to presiding over lower-than-normal interest rates for the last 30 years, QE helps the cause. By removing Treasury and mortgage-backed securities from the market, the market can more easily absorb new Treasury issuance.

Fiscal dominance, as we are experiencing, occurs when monetary policy helps the Treasury fund its debts. Per The CATO Institute:

Fiscal dominance occurs when central banks use their monetary powers to support the prices of government securities and to peg interest rates at low levels to reduce the costs of servicing sovereign debt.

2019 Revisited

In 2019, before the massive pandemic-related deficits, government spending ramped up over the prior few years due to higher spending and tax cuts. In September 2019, the repo markets strained under the pressure of the growing Treasury demands. The banks had plenty of securities but no cash to lend. For more information on the incident and the importance of liquidity in maintaining financial stability, please read our article, Liquidity Problems.

When a bank, broker, or investor can’t borrow money despite being willing to post U.S. Treasury collateral, that is a clear sign that the banking system lacks liquidity. That is exactly what happened in 2019.

The Fed came to the rescue, offering QE and lowering interest rates.

Shortly later, in March 2020, government spending blossomed with the pandemic, and the Fed was quick to help. As we shared earlier, the Fed, via QE, removed over $5 trillion of assets from the financial markets. That amount was on par with the surge of government debt.

The Fed is mandated to manage policy to achieve maximum employment and stable prices. Mandated or not, recent experiences demonstrate the Fed has become the de facto lender to the Treasury, albeit indirectly.

The Fed Is In Handcuffs

While Jerome Powell and the Fed might like to help the government meet their exorbitant funding needs with lower interest rates and QE, they are shackled. Higher inflation resulting from the pandemic and fiscal and monetary policies force them to reduce their balance sheet and keep rates abnormally high.

Unfortunately, as we wrote in Liquidity Problems, the issuance of Treasury debt rapidly drains excess liquidity from the system.

While the Fed hesitates to cut rates or do QE, they may have another trick up their sleeve.

Spreading Rumors

The following is based on rumors from numerous sources about what the Fed and banking regulators may do to alleviate funding pressures and liquidity shortfalls. 

Banks have regulatory limits on the amount of leverage they can employ. The amount is set by the type and riskiness of assets they hold. For instance, U.S. Treasuries can be leveraged more than a loan to small businesses. A dollar of a bank deposit may allow a bank to buy $5 of a Treasury note but only lend $3 to a riskier borrower.

The regulatory structure currently recognizes eight Global Systematically Important Banks (GSIB). They are as follows:  Bank of America, The Bank of New York, Citigroup, Goldman Sachs, JPMorgan Chase, Morgan Stanley, State Street, and Wells Fargo & Company.

Rumor has it that the regulators could eliminate leverage requirements for the GSIBs. Doing so would infinitely expand their capacity to own Treasury securities. That may sound like a perfect solution, but there are two problems: the banks must be able to fund the Treasury assets and avoid losing money on them.  

BTFP To The Rescue Again

A year ago, the Fed created the Bank Term Funding Program (BTFP) to bail out banks with underwater securities. The program allowed banks to pledge underwater Treasury assets to the Fed. In exchange, the Fed would loan them money equal to the bond’s par value, even though the bonds were trading at discounts to par.

Remember, since 2008, banks no longer have to book gains or losses on assets unless they are impaired or sold.

In a new scheme, bank regulators could eliminate the need for GSIBs to hold capital against Treasury securities while the Fed reenacts some version of BTFP. Under such a regime, the banks could buy Treasury notes and fund them via the BTFP. If the borrowing rate is less than the bond yield, they make money and, therefore, should be very willing to participate, as there is potentially no downside.

The Fed still uses its balance sheet in this scheme, but it could sell it to the public as a non-inflationary action, as it did in March 2023 when the BTFP was introduced.

Summary

The federal government’s escalating debt and interest expenses underscore the challenges posed by prolonged deficit spending. The problem has forced the Fed to help the Treasury meet its burgeoning needs. The situation becomes more evident with each passing day.

The recently closed BTFP program and rumors about leverage requirements provide insight into how the Fed might accomplish this tall task while maintaining its hawkish anti-inflationary policy stance.  

The post QE By A Different Name Is Still QE appeared first on RIA.

Read More

Continue Reading

Uncategorized

COVID-19 Infection Increases Risk Of Autoimmune Diseases By Up To 30 Percent: Study

COVID-19 Infection Increases Risk Of Autoimmune Diseases By Up To 30 Percent: Study

Authored by George Citroner via The Epoch Times (emphasis…

Published

5 hours ago

on

March 20, 2024

By

COVID-19 Infection Increases Risk Of Autoimmune Diseases By Up To 30 Percent: Study

Authored by George Citroner via The Epoch Times (emphasis ours),

(Juan Gaertner/Shutterstock)

Surviving COVID-19 may leave you at heightened risk of developing debilitating autoimmune diseases like rheumatoid arthritis and lupus for up to a year after infection, according to new research.

However, the study also found that vaccinating against the virus could significantly lower your chances of developing these potentially life-altering inflammatory conditions.

COVID-19 Infection Severity Plays a Big Role

The study, published in Annals of Internal Medicine, analyzed national claims data from over 10 million Korean and 12 million Japanese patients aged 20 and above diagnosed with COVID-19 between January 2020 and December 2021. The dominant strains were the wild-type virus and the delta variant during this period. COVID-19 patients were compared with matched flu patients and uninfected controls.

A little less than 4 percent of Korean participants had a history of COVID-19, and about 1 percent had a history of flu. Among Japanese participants, about 8 percent had been infected with COVID-19, and slightly less than 1 percent had been infected with flu.

Researchers found that COVID-19 patients had a 25 percent to 30 percent increased risk of new-onset autoimmune rheumatic diseases (AIRDs) 30 days after infection compared to uninfected individuals.

More severe COVID-19 was linked to a greater risk of new-onset, untreated, and treated AIRD, with both wild-type and delta variants associated with AIRD risk. The risk of new-onset AIRD seemed to decline over time and trailed off after the first year.

COVID-19 infection is associated with numerous autoimmune disorders, Dr. Jacob Teitelbaum, a board-certified internist specializing in the treatment of chronic fatigue syndrome and fibromyalgia, told The Epoch Times. “For example, there is a marked increase in hyperthyroidism after COVID caused by autoimmune attack on the thyroid glands,” he said. With the immune system already on high alert from the virus and “having trouble shutting down,” it is not surprising that the body’s own tissues will often become collateral damage, he noted.

“So this new study simply confirms what is already expected,” Dr. Teitelbaum added.

Vaccines Reduce Autoimmune Risk, but Only in Mild Cases

The findings also suggest that COVID-19 vaccination reduced the rate of AIRDs among patients who received one to two or more doses. This reduced risk was observed whether the vaccine used was mRNA-based or viral-vector type.

However, the reduced AIRD risk was only linked to patients with mild COVID-19 infection, not those with moderate or severe infection.

This is noteworthy, given growing evidence suggesting that COVID-19 vaccination could cause new-onset autoimmune diseases, including autoimmune glomerulonephritis, autoimmune hepatitis, and AIRDs.

AIRDs Increase Risk of Other Severe Conditions

AIRDs involve inflammation of the joints or connective tissue caused by attacks from the body’s immune system. These diseases can affect multiple organs and systems, leading to a wide range of symptoms and complications.

Some common AIRDs include:

  • Rheumatoid arthritis (RA): RA is a chronic autoimmune disorder that primarily affects joints, causing inflammation, pain, stiffness, and swelling. Untreated RA can lead to joint damage, deformities, disability, cardiovascular disease, osteoporosis, and lung problems over time.
  • Systemic lupus erythematosus (SLE): SLE is a systemic autoimmune disease affecting various organs and tissues like skin, joints, kidneys, heart, lungs, and brain. Symptoms may include fatigue, joint pain, skin rashes, fever, and organ inflammation. Complications involve kidney damage, cardiovascular disease, neurological disorders, and increased infection susceptibility.
  • Ankylosing spondylitis (AS): AS primarily affects the spine and sacroiliac joints, causing inflammation and eventual vertebrae fusion, leading to spinal stiffness and limited mobility. It can also impact other joints, eyes, and organs. Complications may include spinal deformities, eye inflammation, and cardiovascular problems.
  • Psoriatic arthritis (PsA): PsA is an autoimmune condition with joint inflammation and skin lesions (psoriasis). In addition to joint pain, swelling, and stiffness, PsA can cause nail changes, eye inflammation, and tendon inflammation (enthesitis). Complications could include diabetes and high blood pressure.
  • Sjögren’s syndrome: Sjögren’s syndrome primarily affects moisture-producing glands, leading to dry eyes and mouth. However, it can also cause systemic issues like joint pain, fatigue, and organ involvement of the kidneys, lungs, or nervous system. It increases the risk of lymphoma and other autoimmune diseases.
  • Systemic sclerosis (scleroderma): Scleroderma is characterized by excessive collagen production, causing thickening and hardening of skin and connective tissues. It can also affect internal organs like the lungs, heart, kidneys, and gastrointestinal tract. Complications may include gastrointestinal bleeding, lung and heart problems, and bowel obstruction.

Inexpensive Treatment Available but Ignored: Expert

AIRDs significantly impact quality of life and require long-term management with medications, physical therapy, and lifestyle modifications. Regular monitoring and comprehensive care from health care professionals are essential for managing these conditions and minimizing health risks.

However, effective yet inexpensive treatments for these conditions are largely ignored, Dr. Teitelbaum said.

Low-dose naltrexone, costing less than $1 a day, has been shown to help chronic pain or autoimmune conditions, he added. Additionally, highly absorbed curcumin and Boswellia serrata, found in curcumin, were proven as effective as Celebrex in treating rheumatic arthritis in a head-to-head study, he noted.

Tyler Durden Wed, 03/20/2024 - 02:45

Read More

Continue Reading

International

IVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets

  Credit: IVI IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international…

Published

6 hours ago

on

March 20, 2024

By

 

Credit: IVI

  • IVI will complete the technology transfer by 2025
  • Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international markets

 

March 20, 2024, SEOUL, Republic of Korea and HYDERABAD, India — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, today announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company.

 

Following the signing of a technology license agreement in November last year, IVI has begun providing the technical information, know-how, and materials to produce OCV-S at BE facilities and will continue to support necessary clinical development and regulatory approvals. IVI and BE entered this partnership during an unprecedented surge of cholera outbreaks worldwide and aim to increase the volume of low-cost cholera vaccine in India as well as the global public market.

 

IVI will complete the technology transfer by 2025 and the oral cholera vaccine will be manufactured for India and international markets by Biological E. Limited.

 

Dr. Jerome Kim, Director General of IVI, said: “In an era of heightened risk of poverty-associated infectious diseases such as cholera, the world needs a sustainable source of high-quality, affordable vaccines and committed manufacturers to supply them. We are pleased to partner with Biological E., a company with a proven history of making life-saving vaccines accessible globally, to address this supply gap and protect communities from this deadly, though preventable, disease.”

 

Ms. Mahima Datla, Managing Director, Biological E. Limited, said: “We are glad to be in collaboration with IVI for the manufacture of simplified Oral Cholera Vaccine. Our efforts are aimed to not only combat the disease but to also be part of a sustained legacy of innovation, collaboration, and health stewardship. Together with IVI, we are happy to be shaping a healthier and more resilient future by making this vaccine accessible globally.”

 

This technology transfer and licensing agreement is the sixth of its kind for IVI, transferring such technology to manufacturers in India, the Republic of Korea, Bangladesh, and South Africa. All these partnerships have led to or seek to achieve, pre-qualification (PQ) from the World Health Organization, a designation that enables global agencies such as UNICEF to procure the vaccine for the global market. BE already has 9 vaccines with WHO PQ in its portfolio, and IVI and BE will pursue WHO PQ for OCV-S as well, following national licensure in India.

 

Dr. Julia Lynch, Director of IVI’s Cholera Program, said: “The cholera situation is dire, and the availability and use of oral cholera vaccine is an essential part of a multifaceted approach to cholera control and prevention, especially as outbreaks increase and the global vaccine supply remains strained. With more manufacturers like BE entering the market, the future supply situation looks strong. IVI remains committed to ensuring the availability of the oral cholera vaccine and to developing new and improved vaccines that are equally safe, effective, and affordable and made around the world, for the world.”

 

OCV-S is a simplified formulation of OCV with the potential to lower production costs while increasing production capacity for current and aspiring OCV manufacturers. IVI’s development of OCV-S and ongoing technology transfers are part of an institutional strategy to confront cholera with 3 main goals: 1) Ensure supply of OCV 2) Improve cholera vaccines 3) Support OCV use and introduction. The Bill & Melinda Gates Foundation has been supporting IVI’s cholera program since 2000 and is funding this latest technology transfer to BE.

 

###

 

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

 

 

About Biological E. Limited

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to more than 130 countries and its therapeutic products are sold in India, the USA and Europe. BE currently has 8 WHO-prequalified vaccines and 10 USFDA approved Generic Injectables in its portfolio. Recently, BE has received Emergency Use Listing (EUL) from the WHO for CORBEVAX®, the COVID-19 vaccine. Recently, DCGI has approved BE’S 14-Valent Pneumococcal Conjugate vaccine.

In recent years, BE has embarked on new initiatives for organizational expansion such as developing specialty injectable products for global markets as a means to manufacture APIs sustainably and developing novel vaccines for the global market.

Please follow us on Facebook, LinkedIn and Twitter

 

 

MEDIA CONTACTS

IVI

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int

 

Biological E. Limited

K. Vijay Amruth Raj
Email: Vijay.Kammari@biologicale.com
www.biologicale.com/news

Read More

Continue Reading

Trending